Want to see SYRS full AI Analyst Report?
Syros Pharmaceuticals (SYRS) Stock Price & Analysis
SYRS Stock Chart & Stats
- Day’s Range
- $0.00 - $0.01
- 52-Week Range
- $0.00 - $0.01
- Previous Close
- $0.02
- Volume
- 1.14M
- Average Volume (3M)
- 116.46K
- Market Cap
- $10.73K
- Enterprise Value
- $86.52M
- Total Cash (Recent Filing)
- $58.27M
- Total Debt (Recent Filing)
- $60.23M
- Price to Earnings (P/E)
- 0.0
- Beta
- 9.90
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Market Opportunity
The significant market potential for tamibarotene provides a substantial growth opportunity, positioning Syros to capture a large share of the higher-risk MDS therapeutics market.
Advancement Of Tamibarotene
Successful advancement of tamibarotene could establish it as a new standard of care, significantly enhancing Syros' competitive position in the oncology market.
Reduction In Net Loss
The significant reduction in net loss indicates improved financial management and operational efficiency, enhancing long-term sustainability.
Bears Say
Financial Instability
The negative equity position indicates financial instability, posing risks to Syros' ability to fund operations and invest in growth initiatives.
Lack Of Revenue
The absence of revenue highlights challenges in monetizing its pipeline, which could hinder long-term financial viability and growth prospects.
Cash Depletion
The rapid decrease in cash reserves limits Syros' financial flexibility, potentially impacting its ability to sustain operations and fund R&D activities.
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
What is Syros Pharmaceuticals’s market cap?
When is Syros Pharmaceuticals’s upcoming earnings report date?
How were Syros Pharmaceuticals’s earnings last quarter?
Is Syros Pharmaceuticals overvalued?
Does Syros Pharmaceuticals pay dividends?
What is Syros Pharmaceuticals’s EPS estimate?
How many shares outstanding does Syros Pharmaceuticals have?
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James E. Bradner
- Employees
- 68
- Website
- www.syros.com
- Address
- 35 CambridgePark Drive, Cambridge, MA, 02140, US
Syros Pharmaceuticals (SYRS) Earnings & Revenues
SYRS Earnings Call
Earnings Call SentimentNeutral
The earnings call conveyed a cautiously optimistic outlook, emphasizing the advancement of tamibarotene and its significant market potential, alongside improved financial metrics. However, the lack of revenue and decreased cash reserves present notable concerns.
View all SYRS earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 6 | 8 |
| Technical Analysis | 1 | 6 | 2 |
| Moving Averages | 6 | 0 | 6 |












